Patrick Daly

DocwireNews

Following results from the SONICS trial, which showed <a href="https://medlineplus.gov/druginfo/meds/a622025.html">levoketoconazole</a> was effective in endogenous Cushing syndrome, researchers designed the LOGICS study to evaluate drug-specific cortisol normalization. According to the authors, treatment with levoketoconazole induced frequent normalization of mean urinary-free cortisol (mUFC) and improvements in patients&rsquo; lipid profiles. The data were reported in Pituitary.The phase 3 placebo-controlled LOGICS study enrolled 79 patients to titration-maintenance for 14 to 19 weeks with levoketoconazole, followed by randomized withdrawal and restoration phases of approximately 8 weeks each. The primary end point was loss of response, defined as mUFC&thinsp;&gt;1.5&thinsp;&times;&thinsp;upper limit of normal.A total of 39 patients who held a stable titration-maintenance dose for 4 weeks or more&mdash;plus 5 patients who completed the SONICS trial&mdash;were randomized to levoketoconazole (n=22) or placebo (n=22). During the withdrawal phase, 21 (95.5%) patients on placebo lost mUFC response compared with 9 (40.9%) patients who continued levoketoconazole (&ndash;54.5%; 95% CI, &ndash;75.7 to &ndash;27.4; P=.0002).After the withdrawal phase, 11 (50.0%) levoketoconazole patients achieved mUFC normalization compared with 1 (4.5%) placebo patient (45.5%; 95% CI, 19.2-67.9; P=.0015). The authors noted restarting levoketoconazole reversed loss of cortisol control in most placebo patients.Adverse events were observed in 89% of levoketoconazole patients, with the most common events being nausea (29%) and hypokalemia (26%). Additional adverse events of interest included liver-related events (10.7%), QT interval prolongation (10.7%), and adrenal insufficiency (9.5%).Limitations of the study included the short withdrawal phase, and the authors noted that several patients in the placebo group required early rescue treatment. They also acknowledged the presence of baseline differences between the groups, though they stated these differences did not meaningfully affect interpretation of the data.Overall, the study&rsquo;s authors attributed treatment benefits to levoketoconazole given the &ldquo;loss of benefit upon withdrawal to placebo and restoration upon reintroduction of active therapy.&rdquo; They supported the use of levoketoconazole in patients with endogenous Cushing syndrome.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Establishing Levoketoconazole-Specific Benefits in Cushing Syndrome

Endocrinology

Following results from the SONICS trial, which showed levoketoconazole was effective in endogenous Cushing syndrome, researchers designed the LOGICS study to evaluate ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe